Aurobindo Pharma is doing pretty well today morning, trading higher by around 1.5% at Rs.867, with an intra day high at Rs,880. Its 52-week high is at Rs.908.

The stock is reacting positively after the company announced that it has received the final US FDA approval to manufacture and market Amoxixilin for oral suspension.

Giving further details, the Aurobindo has stated that this ANDA was approved out of unit 12, semi-synthetic Penicillin facility in Hyderabad. The drug has a market size of $ 19 million for the twelve month period ending July 2014.